I. E. L. M. Kuppens

Statistics

Publications

Citations

424

H-Index

Active since

2004

Affiliations

The Netherlands Cancer Institute(Current)

Slotervaartziekenhuis

Utrecht University

University Medical Center Utrecht

I. E. L. M. Kuppens is an author at The Netherlands Cancer Institute specializing in pharmacology, clinical pharmacology, and pharmacokinetics of anticancer drugs.

Publications per year

2004–2007

Publications

A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

I. E. L. M. Kuppens, Els O. Witteveen, Roxanne C. Jewell et al. · Clinical Cancer Research · 2007 · 176 citations

Medicine, Oncology, Pharmacology +16

Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093)

I. E. L. M. Kuppens, Tessa M. Bosch, M. J. van Maanen et al. · Cancer Chemotherapy and Pharmacology · 2004 · 85 citations

Pharmacy, Pharmacokinetics, Pharmacology +9

Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry

I. E. L. M. Kuppens, M. J. van Maanen, Hilde Rosing et al. · Biomedical Chromatography · 2004 · 58 citations

Pharmacy, Pharmaceutical Analysis, Pharmacology +17

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

Nadja E. Schoemaker, I. E. L. M. Kuppens, Vladimir Moiseyenko et al. · British Journal of Cancer · 2004 · 35 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Phase I study of an oral formulation of irinotecan administered daily for 14�days every 3�weeks in patients with advanced solid tumours

Nadja E. Schoemaker, I. E. L. M. Kuppens, W.W. ten Bokkel Huinink et al. · Cancer Chemotherapy and Pharmacology · 2004 · 29 citations

Medicine, Oncology, Pharmacology +14

1–5 of 7